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Abstract
Glutamate dehydrogenase (GDH), encoded by GLUD1,
participates in the breakdown and synthesis of glutamate,
the main excitatory neurotransmitter. In the CNS, besides its
primary signaling function, glutamate is also at the crossroad
of metabolic and neurotransmitter pathways. Importance of
brain GDH was questioned here by generation of CNS-
speciﬁc GDH-null mice (CnsGlud1/); which were viable,
fertile and without apparent behavioral problems. GDH immu-
noreactivity as well as enzymatic activity were absent in Cns-
Glud1/ brains. Immunohistochemical analyses on brain
sections revealed that the pyramidal cells of control animals
were positive for GDH, whereas the labeling was absent in
hippocampal sections of Cns-Glud1/ mice. Electrophysio-
logical recordings showed that deletion of GDH within the CNS
did not alter synaptic transmission in standard conditions.
Cns-Glud1/ mice exhibited deﬁcient oxidative catabolism of
glutamate in astrocytes, showing that GDH is required for
Krebs cycle pathway. As revealed by NMR studies, brain
glutamate levels remained unchanged, whereas glutamine
levels were increased. This pattern was favored by up-
regulation of astrocyte-type glutamate and glutamine trans-
porters and of glutamine synthetase. Present data show that
the lack of GDH in the CNS modiﬁes the metabolic handling of
glutamate without altering synaptic transmission.
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Glutamate is the major excitatory neurotransmitter in mam-
malian CNS and is involved in mechanisms of synaptic
plasticity, memory, and neuronal or glial cell death. Upon
glutamatergic transmission, intersynaptic glutamate clearance
is achieved mostly by astrocytes (Bak et al. 2006), preventing
toxic accumulation in the extracellular space. In the astro-
cytes, glutamate is either amidated to glutamine via glutamine
synthetase and then recycled back to neurons as part of
glutamate–glutamine cycle. Alternatively, glutamate is
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deaminated to yield a-ketoglutarate, followed by further
oxidation in the tricarboxylic acid (TCA) cycle to generate
ATP (Yu et al. 1982; McKenna et al. 1996). Such an
essential process is commonly attributed to both glutamate
dehydrogenase (GDH) and transaminases, although their
relative importance has not been established yet. GDH, in
rodents encoded solely by GLUD1 (Michaelidis et al. 1993),
is a mitochondrial enzyme catalyzing either the anabolic
reductive amination of a-ketoglutarate producing glutamate
or, conversely, the catabolic oxidative deamination of gluta-
mate (Karaca et al. 2011). In CNS, GDH is predominantly
expressed in astrocytes and to lower levels in neurons (Rothe
et al. 1994; Mastorodemos et al. 2005). To date, the putative
importance of GDH as a player in balanced glutamate–
glutamine cycle activity and as a supplier of precursors for
glutamatergic neurotransmission remains to be established,
essentially because we lack loss-of-function models.
Abnormal glutamatergic transmission has been associated
with major neurodegenerative diseases (Kim et al. 2011).
Accordingly, attenuation of glutamate toxicity is foreseen as
one possible therapeutic strategy. Recent characterization of
transgenicmice over-expressingGlud1 inCNSneurons showed
enhanced glutamate release and neuronal damages (Bao et al.
2009). In this context,GDH represents a promising target for the
study of glutamate-associated neurodegenerative diseases.
This study reports the ﬁrst mouse model with brain-speciﬁc
ablation of GDH, named Cns-Glud1/.We questioned the
putative importance of GDH in synaptic transmission and in
the maintenance of glutamate–glutamine balance. Our data
show that the lack of Glud1 in brain inhibited GDH activity
regardless of enzymatic direction, modiﬁed glutamate han-
dling, decreased glutamate catabolism to CO2, and increased
glutamine levels; without affecting synaptic transmission.
Material and methods
Brain-specific GDH knockout mouse Cns-Glud1/
Glud1 ﬂoxed (Glud1lox/lox) mice (Carobbio et al. 2009) were
crossed with mice expressing Cre recombinase under the control
of nestin cis-regulatory sequence (Tronche et al. 1999). Heterozy-
gous Cns-Glud1/+ were crossed with Glud1lox/lox mice to obtain
homozygous Cns-Glud1/. Animals were maintained on a mixed
(C57BL/6J x 129/Sv) genetic background to avoid inbred strain-
speciﬁc phenotypes. As control mice, we used Glud1lox/lox litter-
mates of Cns-Glud1/ to optimize standardization of the genetic
background between the two groups. Both male and female animals
were studied for some representative parameters. As no gender
differences were noticed, detailed analyses presented here are only
from males. Mice were maintained in our animal facility according
to procedures approved by the animal care and experimentation
authorities of the Canton of Geneva.
GDH expression and activity assessment
Glud1 deletion in knockout brains was assessed at the protein level
by immunoblotting on tissues collected from killed mice in
radioimmunoprecipitation assay buffer. Protein extracts were
separated in bis-acrylamide 10% gel and probed with anti-GDH
(Rockland, Gilbertsville, PA, USA) and anti-actin (Millipore, Billerica,
MA, USA) primary antibodies as described (Carobbio et al. 2004).
Bands were revealed by horseradish peroxidase detection system.
GDH enzymatic activity was measured in brains collected in ice-cold
saline before homogenization in 50 mM Tris/HCl pH 7.4, 0.5 mM
EDTA, 1 mM ß-mercaptoethanol in glass potter. After 40 min
centrifugation at 8000 g, supernatants were assayed for enzymatic
activity (Carobbio et al. 2004). For immunohistochemistry, hippo-
campi were ﬁxed overnight in 4% paraformaldehyde, dehydrated
and embedded in parafﬁn. Sections (5 lm) treated with citrate
buffer, pH 6, were incubated overnight with rabbit anti-GDH
(Rockland) antibody at 4°C. They were then incubated with Alexa
488-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA, USA)
antibody and analyzed by confocal microscopy using a 60x
objective (Olympus FV300 confocal LSM, Hamburg, Germany).
Electrophysiology
Hippocampal slices (400 lm) were prepared from 4.5- to 5.5-month-
old Cns-Glud1/ and Glud1lox/lox control mice as described previ-
ously (Quintana et al. 2006). Slices were maintained in an interface
chamber at 32°C (95% O2, 5% CO2) and perfused with buffer
containing (in mM): 124 NaCl, 1.6 KCl, 2.5 CaCl2, 1.5 MgCl2, 24
NaHCO3, 1.2 KH2PO4, 10 glucose, and 2 ascorbic acid, pH 7.4.
Extracellular ﬁeld excitatory post-synaptic potentials (fEPSPs) were
evoked by a bipolar stimulating electrode made with two twisted
strands of nichrome wires (50 lm of diameter), triggered with a
Master-8 (AMPI, Jerusalem, Israel) and placed on a group of Schaffer
collaterals. fEPSPs were evoked by stimulation of a group of Schaffer
collaterals and recorded in the stratum radiatum of CA1 using an
Axoclamp 2A ampliﬁer (Molecular Devices, Sunnyvale, CA, USA).
Paired-pulse facilitation was elicited by repeated pulses at 50 ms
interval. Input/output relationship was determined by monitoring
responses to increased stimulation intensities. Long-term potentiation
(LTP) was induced by theta burst stimulation (ﬁve trains at 5 Hz
composed each of four pulses at 100 Hz, repeated twice at 10 s
intervals) and the level of potentiation assessed by measuring the
increase in averaged amplitude and slope of 10 responses of the
baseline, with 10 responses evoked 60 min after stimulation.
Cultures of astrocytes
Astrocytes were cultured from dissociated cerebella of 7-day-old
mice as detailed previously (Hertz et al. 1989). To obtain single-cell
suspension, cerebella were dissected and mechanically dissociated
by passing the tissue through 80 lm nylon sieves into Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, MO,
USA) supplemented with 6 mM glucose, 2.5 mM glutamine, and
20% fetal bovine serum. The cell suspension was seeded in 25 cm2
ﬂasks, corresponding to 0.8 mice/ﬂask. Cells were maintained in
culture for 3 weeks prior to experiments and serum was reduced to
15% the second week. Then, astrocytes were trypsinized and
replated in 24- or 6-well plates and maintained for the third week in
a medium containing 10% serum. Stellation of the cells was induced
by 0.25 mM dibutyryl-cAMP (Sigma-Aldrich).
CO2 production by astrocytes from glutamate
CO2 production was determined as previously described (Frigerio
et al. 2010). Prior to the experiment, the astrocytes were incubated
© 2012 The Authors
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for 1 h in serum-free DMEM without glucose and glutamine.
Astrocytes were subsequently incubated in DMEM containing
2.5 mM glucose and 250 lM labeled glutamate (0.1 lCi of L-
[U-14C]glutamate, #0165A American Radiolabeled Chemicals Inc.,
St.Louis, MO, USA) for 1 h at 37°C. During the incubation,
generated CO2 was trapped on 3MM chromatography paper soaked
in 2 M NaOH. Metabolic activity was stopped by placing the plates
at 20°C. The next day, 14CO2 radioactivity was quantiﬁed in a
liquid scintillation ß-counter and protein from cell extracts deter-
mined for normalization using Bradford assay.
NMR measurements of brain metabolites
Anesthesia was maintained at 1.3 ± 0.2% of isoﬂurane in oxygen,
body temperature was kept at 36.5 ± 0.2°C. Spectra were acquired
on an actively shielded 9.4 T/31 cm INOVA animal scanner
(Varian/Magnex Scientiﬁc, Palo Alto, CA, USA) using the
SPECIAL spectroscopy sequence (Mlynarik et al. 2006). This
technique enables to measure short-echo-time spectra with enhanced
signal intensity from the excited volume. A 14-mm-diameter two-
loop quadrature coil was used both for RF excitation and signal
reception. Field homogeneity was adjusted using the FASTMAP
protocol (Gruetter and Tkac 2000). A VOI having the nominal size
of 22–30 lL (typically 3 mm 9 2.5 mm 9 3 mm) was selected in
striatum, TR was 4 s and TE was 2.7 ms. Signal from the outer
volume was suppressed by four blocks of slice-selective pulses,
water signal was suppressed by the VAPOR sequence (Tkac et al.
1999). The 160 scans collected in 10 min provided spectra with
excellent SNR. Absolute concentrations of metabolites were
obtained by LCModel using unsuppressed water signal as a
reference resulting in a neurochemical proﬁle of more than 18
metabolites. The Cramer–Rao lower bounds for concentrations of
the most abundant metabolites were 1–2%.
Expression analysis by quantitative RT-PCR and immunoblotting
Total RNA was extracted from brains collected from control and Cns-
Glud1/ mice by peqGOLD Trifast (Peqlab, Erlangen, Germany).
Target genes were ampliﬁed by Real-Time PCR (StepOnePlus,
Applied Biosystems, Foster City, CA, USA), normalized to cyclophil-
lin levels. Following primers were used (forward and reverse primers):
glutamine synthetase, 5′-CAGGCTGCCATACCAACTTCA-3′, 5′- TG
GCCTCCTCAATGCACTTC-3′; excitatory amino acid transporter 1
(EAAT1), 5′-TAACGAAGCCATCATGCGATT-3′, 5′-CCCTGCGAT
CAAGAAGAGGAT-3′; EAAT2, 5′-AGGTCAGATTGTGACTGTA
AGCCTTA-3′, 5′-CCGGCGCTGGGAATACT-3′; SNAT3, 5′-GCTGC
CCATATATACAGAGCTCAAG-3′, 5′-GACAGCAATGGACAGG
TTGGA-3′; SNAT7, 5′-GTGTGCTCACCTCCTATCCAATCT-3′,
5′-CACGGGCATCCCCTTGTAG-3′; glutaminase, 5′-TCAAAGG
GTGAAGTCGGTGAT-3′, 5′- AATCCC GCTGCTCCATGTC-3′;
vesicular glutamate transporter 1 (vGLUT1), 5′-GGAGGCCAGAT
CGCTGACT-3′, 5′-AGCTTTCGCACGTTGGTAGTG-3′; cyclo-
phillin, 5′-ATGGCAAATGCTGGACCAA-3′, 5′-GCCATCCAGC
CATTCAGTCT-3′.
At the protein level, immunoblotting analyses were performed on
tissues collected in ristocetin-induced platelet agglutination buffer as
described above. Following bis-acrylamide gel electrophoresis and
transfer, proteins were detected by using primary antibodies against
glutamine synthetase (Millipore), EAAT2/SLC1A2 (Cell signaling,
Beverly, MA, USA), SNAT3/SLC38A3 (Proteintech, Chicago, IL,
USA), and ezerin (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) serving as loading control.
Statistical analysis
Unless otherwise stated, such as for electrophysiology, statistical
signiﬁcance was determined by Student’s t-test. A p value < 0.05
was used to indicate a signiﬁcant difference.
Results
Assessment of brain-specific GDH-knockout mouse,
Cns-Glud1/
Cns-Glud1/ mice were generated by crossing Glud1lox/lox
with Nestin-Cre mice. Deletion was successful and speciﬁc
for brain, as GDH expression was fully preserved in other
tissues known to express GDH (Fig. 1a). We observed
abrogation of GDH enzymatic activity in brain homogenates
of Cns-Glud1/, both in oxidative deamination and in
reductive amination directions (Fig. 1b and c). The hippo-
campal CA1 region, rich in glutamatergic synapses, was
analyzed by immunohistochemistry. Dense GDH labeling
was observed in controls, while the signal was absent in
hippocampal sections of Cns-Glud1/ mice (Fig. 1d).
Homozygous mice were viable and fertile and did not
exhibit apparent behavioral problems when handling animals
for regular cares on a daily basis over a period of more than
4 years.
Ablation of GDH in brain does not affect synaptic
transmission
The fEPSPs showed identical electrophysiological properties
for Cns-Glud1/ and control mice, regarding synaptic
transmission and synaptic plasticity. As shown in Fig. 2a–d,
evoked fEPSPs were not different in terms of time (decay:
6.49 ± 0.59 vs. 7.00 ± 0.78 ms, p = 0.36, unpaired t-test),
paired-pulse facilitation (37.2 ± 3.1 vs. 36.0 ± 7.6%,
p = 0.34, unpaired t-test) as well as for the input–output
relationship of their amplitude and slope (p values of 0.67
and 0.36, respectively; two-way ANOVA with Bonferroni post-
test). In addition, Cns-Glud1/ mice showed normal LTP
(Fig. 2e) with similar rates of success compared with control
mice (Fisher’s exact test, Fig. 2f) and similar levels of fEPSP
slope potentiation (51 ± 31 vs. 46 ± 18%, respectively,
p = 1, Mann–Whithney U-test, Fig. 2g). Overall, these
electrophysiological recordings showed that deletion of
GDH within the CNS did not alter synaptic transmission
in standard conditions. However, it remains to be determined
if chronic glutamate exposure would result in similarly
unaltered glutamatergic activity.
Glutamate handling is affected in Cns-Glud1/ brain
Glutamate may serve as energy substrate via GDH-depen-
dent deamination to yield a-ketoglutarate followed by further
oxidation in the TCA cycle (Fig. 3a). Oxidative catabolism
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of glutamate was reduced by about 30% in Cns-Glud1/
astrocytes compared to controls, as measured by 14CO2
production from [U-14C]glutamate (Fig. 3b). Thus, the lack
of glutamate oxidation via GDH was not compensated by
transaminase pathways. Of note, intrabrain levels of amino-
transferase substrates alanine and aspartate were not changed
in Cns-Glud1/ animals, as measured by NMR (Fig. 3c).
Interestingly, intrabrain glutamate levels were similar
between control and Cns-Glud1/ mice (Fig. 3c). An
alternative metabolic fate for glutamate in astrocytes is its
amidation to glutamine, catalyzed by glutamine synthetase.
Then, part of newly synthesized glutamine leaves the astro-
cytes, mainly through speciﬁc glutamine transporter SNAT3
(Fig. 3a). We observed higher intrabrain concentrations of
glutamine in Cns-Glud1/ mice (Fig. 3c) accompanied by
increased expression of both glutamine synthetase and
astrocyte-speciﬁc glutamate transporters EAAT1 and EAAT2,
as well as the glutamine transporter SNAT3 (Fig. 3d and e).
These results indicate that in cultured astrocytes originating
from Cns-Glud1/ mice and exhibiting reduced CO2
production from glutamate, glutamate metabolism may be
directed toward glutamine synthesis and export.
Glutamine synthesized by astrocytes is taken up by
neurons, notably through recently identiﬁed neuronal gluta-
mine transporter SNAT7 (Hagglund et al. 2011). Glutamine
is then converted back to glutamate in pre-synaptic terminals
by the action of glutaminase before translocation into
secretory vesicles via vGLUT1 (Fig. 3a). In Cns-Glud1/
mice, the expression of glutaminase and vGLUT1 remained
unchanged (Fig. 3d). Finally, intrabrain GABA concentra-
tions were comparable between control and Cns-Glud1/
mice, arguing against accumulation of this decarboxylation
product of glutamate (Fig. 3c).
Altogether, these data show that the lack of GDH in brain
affects glutamate handling mainly in astrocytes, decreasing
glutamate catabolism and increasing intrabrain glutamine levels.
Discussion
Glutamate is the major excitatory neurotransmitter in the
brain, with about 40% of all synapses being glutamatergic
(Fairman and Amara 1999). Glutamate may also exert
neurotoxic actions leading to neuronal death. Accumulation
of extracellular glutamate and subsequent over-stimulation of
glutamatergic receptors is harmful. Thus, tight glutamate
handling in the CNS is crucial for maintenance of its integrity.
Abnormalities in this process are associated with several
neurodegenerative diseases; such as Parkinson’s disease,
epilepsy, schizophrenia, and Alzheimer’s disease (Kim et al.
2011). Animal models lacking glial glutamate transporter
Eaat2 (Slc1a2, Glt-1) exhibit accumulation of extracellular
glutamate and extensive brain damages (Rothstein et al.
1996; Tanaka et al. 1997). Regarding GDH, higher expres-
sion has been reported in Alzheimer’s brains (Burbaeva et al.
2005; Owen et al. 2009) and lower activity in temporal cortex
of epileptic patients (Malthankar-Phatak et al. 2006).
Initial insights into Cns-Glud1/ mice show that (i) both
oxidative deamination and reductive amination activities of
GDH were inhibited, (ii) GDH abrogation did not affect
synaptic transmission, (iii) intrabrain levels of glutamate
remained similar to controls. Cultured astrocytes incubated
with labeled glutamate revealed that the lack of GDH
impaired glutamate catabolism in the TCA cycle, as demon-
strated by lower CO2 production. Interestingly, this was not
compensated by transamination pathways. It should be noted
that results obtained from measurements of glutamate-
(a)
(b)
(d)
(c)
Fig. 1 Assessment of brain-speciﬁc glutamate dehydrogenase (GDH)-
knockout mouse, Cns-Glud1/. (a) Brain-speciﬁc Glud1 deletion was
controlled by immunoblotting for GDH expression and compared to
non-excitable tissues collected from control (Glud1lox/lox) and CNS-
speciﬁc Glud1-knockout Cns-Glud1/ mice. Actin served as loading
control. Immunoblots are representative of three independent prepa-
rations. (b, c) Enzymatic activity of GDH measured in brain extracts of
control and Cns-Glud1/ mice measured in both oxidative (b) and
reductive (c) directions, using glutamate and a-ketoglutarate as
substrates, respectively. Values are means ± SE, n = 5, **p < 0.01
versus control. (d) Representative immunohistochemical labeling for
GDH on CA1 ﬁeld of the hippocampus. Right panels are 5x enlarge-
ments of left panels.
© 2012 The Authors
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derived CO2 did not take into account a potentially elevated
glutamate uptake by Cns-Glud1/ astrocytes, indicated by
the augmented EAAT expression in the whole brain.
Enhanced glutamate uptake would lead to higher speciﬁc
radioactivity of intracellular glutamate in Cns-Glud1/
astrocytes, and thus, the reduced CO2 production observed
in these astrocytes might be underestimated. Nevertheless,
the reduced capacity of glutamate catabolism did not result in
accumulation of glutamate in Cns-Glud1/ brains. Instead,
glutamate might be redirected to glutamine synthesis and
export out of the astrocytes, as indicated by the observed
up-regulation of astrocyte-type glutamine transporter SNAT3
and glutamine synthetase in brains of Cns-Glud1/ mice.
Before this ﬁrst mouse model of brain-speciﬁc loss-of-
function of GDH, Bao and colleagues reported the opposite
maneuver by generating transgenic mice over-expressing
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Fig. 2 Ablation of Glutamate dehydrogenase (GDH) in brain does not
affect synaptic transmission. (a) Illustration of two evoked ﬁeld excit-
atory post-synaptic potentials (fEPSPs) separated by 50 ms in control
(Ctrl) and Cns-Glud1/ (KO) hippocampal slices, revealing similar
levels of paired-pulse facilitation. Arrowheads indicate stimulation of
Schaffer collaterals. (b) Decay time of evoked fEPSPs recorded in
control versus Cns-Glud1/ mice. (c) Magnitude of paired-pulse
facilitation (PPF, in %) of evoked fEPSPs recorded in control versus
Cns-Glud1/ mice. (d) Input–ouput curve of fEPSP slope recorded in
control versus Cns-Glud1/ mice. (e) Representative Long-Term
Potentiation (LTP) experiment performed on a hippocampal slice of a
Cns-Glud1/ animal. Dots represent values of fEPSP slope recorded
every 30 s. LTP was induced by theta burst stimulation (arrow). (f)
Proportion of slices that showed a least a 20% increase in EPSP slope
60 min after stimulation in control and Cns-Glud1/ animals. (g)
Changes in EPSP slope (in %) measured 60 min after stimulation in
control and Cns-Glud1/ mice. (b–d): values are means ± SD, n = 12
slices out of ﬁve animals in each group. (f–g): n = 9 slices out of four
animals in each group.
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GDH in neurons (Bao et al. 2009). In this gain-of-function
model, GDH levels and activity are increased by about 30%
and 40%, respectively. These mice exhibit increased
depolarization-evoked glutamate release, increased fre-
quency and amplitude of hippocampal spontaneously
occurring synaptic events (mEPSC), diminished LTP of
synaptic activity, and age-associated neuronal losses (Bao
et al. 2009).
In the CNS, glutamate de novo synthesis is mainly
contributed by glucose as the source of precursors for the
TCA cycle intermediate, a-ketoglutarate, via pyruvate
carboxylation in astrocytes. However, the amination forming
glutamate has been suggested to occur via either GDH or
transamination pathways, i.e., branched-chain aminotransfe-
rases. In the over-expression model, increased GDH levels
speciﬁcally in neurons led to an increased production of
glutamate (Bao et al. 2009). In the Cns-Glud1/ model
lacking GDH, such a pathway was abrogated and we
additionally observed reduced glutamate breakdown. There
was neither over-excitability nor hypo-excitability, indicating
that glutamate homeostasis was maintained, pending
increased formation of glutamine. Present data on Cns-
Glud1/ model highlight the ﬁne tuning and compartmen-
talization of glutamate–glutamine handling and open new
avenues for further studies investigating the contribution of
GDH in neurodegenerative diseases.
(a)
(b)
(d)
(e)
(c)
Fig. 3 Glutamate handling is affected in Cns-Glud1/ brain. (a)
Simpliﬁed representation of glutamate fates in astrocytes and neurons
(a-ketoglutarate, aKG; alanine, Ala; alanine aminotransferase, ALT;
aspartate, Asp; aspartate aminotransferase, AST; excitatory amino
acid transporters 1/2, EAAT 1/2; glutamate dehydrogenase, GDH;
glutamine, Gln; glutaminase, GLS; glutamate, Glu; glutamine synthe-
tase, GS; oxaloacetate, OA; pyruvate, Pyr; sodium-coupled amino acid
transporters 3/7, SNAT 3/7; vesicular glutamate transporter 1,
vGLUT1). (b) Glutamate catabolism was determined in astrocytes from
control and Cns-Glud1/ mice by measuring 14CO2 production from
L-[U-14C]glutamate (250 lM); n = 7, **p < 0.01 versus control. (c)
NMR analysis of brain metabolites in control and Cns-Glud1/ mice;
n = 11, *p < 0.05 versus control. (d) Gene expression of enzymes and
transporters implicated in CNS glutamate pathways in brains of control
and Cns-Glud1/mice. Values are normalized to cyclophillin; n = 4–6,
*p < 0.05 and **p < 0.01 versus control. (b–d): Values are
means ± SE. (e) Representative immunoblotting showing protein
levels of genes exhibiting the major changes at mRNA levels (d) in
control and Cns-Glud1/ brains (changes on average versus control:
GS, + 28%, p < 0.01; EAAT2, + 38%, p < 0.05; SNAT3, + 34%
p < 0.01; n = 56 mice). Ezerin served as loading control and each
lane corresponds to brain extract from one mouse.
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